Key Drivers
- Strong liquidity
- High cash burn
- Negative FCF
AIAI Summary
Beam should be revalued as an execution-stage, single-product commercial story—its large cash runway and regulatory alignment for a potential 2026 risto‑cel BLA materially increase near-term upside but make valuation highly dependent on flawless filing, manufacturing scale-up, and drawdown of the Sixth Street facility. Monitor BLA timing, additional facility draws, and early commercial/scale-up evidence as the decisive catalysts that will either validate the price or trigger sharp downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •High cash burn
- •Negative FCF
BEAM has a strong liquidity and low-leverage balance sheet but is undermined by heavy R&D/opex burn, negative FY2025 profitability and free cash flow, high valuation multiples, and pronounced intra-year volatility despite a strong Q4.
Price Behavior
Key Price Behavior Insights:
- •Below SMA
- •Elevated volatility
- •Mid‑$20s support
Over the last month the price dropped ~10–11% to $24.63, trading well below the last-month SMA (~$27.00) with elevated volatility between $32.29 and $24.63, signaling short-term bearish momentum but some buying interest in the mid–high $20s.
~25% swing from $32.29 to $24.63 over the last month indicating heightened short-term risk
Sentiment & News
Key News Insights:
- •Surprising revenue beat
- •Mid‑2029 runway
- •Risto‑cel momentum
Beam's strong Q4 beat, $500M financing (with $100M funded), and clinical/pipeline progress (risto‑cel, PKU program) have driven analyst upgrades and ~23% share gains while extending cash runway to mid‑2029.
The financing plus unexpected revenue and clinical data should bolster near‑term stock support, though execution and competitive risks may cause volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings